β-D-Glucan: Introduction, Principle, Clinical Significance, and Keynotes

Introduction

β-D-Glucan (BDG) is a polysaccharide component of the fungal cell wall, widely present in species such as Candida, Aspergillus, Fusarium, and Pneumocystis jirovecii. Since it is released into the bloodstream during invasive fungal infections (IFIs), detection of BDG has become a valuable non-culture-based diagnostic biomarker. The BDG test is often used as part of fungal disease screening in immunocompromised patients, including those with cancer, transplants, or prolonged neutropenia.

Principle

The assay is based on the colorimetric detection of (1→3)-β-D-glucan using the Limulus Amebocyte Lysate (LAL) pathway. When BDG is present in the patient’s serum, it activates the factor G pathway in the LAL reagent derived from horseshoe crab blood. This triggers a cascade of enzymatic reactions, resulting in a measurable color change or turbidity that correlates with the amount of BDG present. The test is performed on serum samples, with a cutoff value (commonly ≥80 pg/mL) used to indicate positivity.

Clinical Significance

• Early Detection of IFIs
  • Detects a wide range of fungi, including Candida, Aspergillus, and Pneumocystis jirovecii.
  • Useful for high-risk patients before culture or imaging results are available.
• Non-Invasive Diagnostic Tool
  • Requires only serum samples, avoiding the need for invasive biopsies.
• Broad Coverage
  • Detects multiple fungi at once, unlike antigen-specific tests (e.g., galactomannan).
• Limitations
  • Does not detect Cryptococcus or Mucorales (as they lack significant BDG).
  • False positives may occur due to hemodialysis with cellulose membranes, certain antibiotics (e.g., amoxicillin-clavulanate), IV immunoglobulins, or bacterial infections.
• Monitoring Therapy
  • Serial BDG measurements can be used to monitor antifungal treatment response or relapse.

Keynotes

1. β-D-Glucan is a sensitive but non-specific biomarker for invasive fungal infections.
2. Best used as a screening tool in high-risk patients in combination with clinical, radiological, and microbiological findings.
3. Negative BDG results reduce the likelihood of IFIs, but a positive result requires careful interpretation.
4. Works synergistically with galactomannan assay, culture, PCR, and imaging for a definitive diagnosis.
5. Particularly valuable for diagnosing Pneumocystis pneumonia (PCP) in HIV and immunocompromised patients.

Further Readings

• https://mft.nhs.uk/app/uploads/2024/11/Fungal-beta-D-glucan-assay.pdf
• https://pmc.ncbi.nlm.nih.gov/articles/PMC7387835/
• ttps://academic.oup.com/cid/article/72/Supplement_2/S102/6168274
• https://www.sciencedirect.com/science/article/pii/S2950194625001621
• https://pubmed.ncbi.nlm.nih.gov/23850953/
• https://www.sciencedirect.com/science/article/abs/pii/S0732889323002274
• https://www.mdpi.com/1422-0067/18/9/1906
• https://www.mdpi.com/2309-608X/8/12/1262
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5008300/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC12068012/
• https://encyclopedia.pub/entry/10668
• https://www.sciencedirect.com/science/article/pii/S1359511324003088
• https://pmc.ncbi.nlm.nih.gov/articles/PMC9783846/
• https://www.tandfonline.com/doi/full/10.1080/14787210.2017.1401467
• https://academic.oup.com/cid/article/52/6/750/361658
• https://www.sciencedirect.com/science/article/pii/S0196439925000017